Clinical trials: HIV Coinfection
HIV Infections
Kaletra Monotherapy in HIV/HCV Co-infected Subjects
The study has been designed to test the hypothesis that in patients co-infected with HIV and HCV who exhibit maximal virologic suppression on a double class antiretroviral (ARV) regimen, including two Nucleoside Reverse…
- Trial name
- NCT00508222
- Testing
- Kaletra Tablets
- Where
- 2 sites in Canada
- Volunteers
- 22 people
- Sponsor
- Ottawa Hospital Research Institute
HIV Coinfection
HIV And Parasitic Infection (HAPI) Study
The overall goal of this study is to determine if periodic de-worming of persons living with HIV in intestinal parasite-endemic regions will lead to decreased morbidity and mortality associated with HIV by reducing immune…
- Trial name
- HAPI (NCT05323396)
- Testing
- Antiparasitic medication
- Where
- Malawi
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections, Hepatitis B
Prospective Cohort of HIV/HBV-coinfected Patients in Europe
The overall aim of the project is to establish an international multi-cohort research platform of HIV/HBV-coinfected individuals treated with tenofovir to improve our understanding of the determinants of treatment outcomes.
- Conditions
- HIV Infections, Hepatitis B, Coinfection
- Trial name
- Euro-B (NCT04984772)
- Volunteers
- 1,107 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Non-HIV Patients With Pneumocystis Jiroveci Pneumonia
Assessment of CMV-specific ELISPOT Assay for Predicting CMV Co-infection in Patients With Pneumocystitis Pneumonia (ACE-PCP)
PCP (Pneumocystis jiroveci pneumonia) is one of the important opportunistic infections in immunocompromised patients including HIV-infected patients, transplant recipients, and immunosuppressant users.
- Trial name
- NCT02109887
- Where
- South Korea
- Volunteers
- 76 people
- Sponsor
- Asan Medical Center
HIV Infections, Hepatitis C
Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users
The purpose of this study is to compare how safe, tolerable, and effective a novel drug, raltegravir, is to a commonly used combination, atazanavir/ritonavir, as initial treatment in HIV/Hepatitis C co-infected injecting drug…
- Trial name
- NCT01105611
- Testing
- Raltegravir, Atazanavir/Ritonavir
- Where
- 2 sites in Ireland
- Volunteers
- 40 people
- Sponsor
- St. James's Hospital, Ireland
HIV Infection, Hepatitis C Infection
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
Infection with hepatitis C virus (HCV) can cause liver scarring, or cirrhosis, and this usually occurs more rapidly among people infected with both HCV and human immunodeficiency virus (HIV).
- Trial name
- NCT00991289
- Testing
- Nitazoxanide (NTZ), Pegylated interferon alfa-2a (PEG), Ribavirin (RBV)
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 68 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Hiv
Pharmacokinetics of Twice or Once Daily DTG (50mg) in Children With HIV and TB
Stage 1 proposed study will provide evidence to support the use of twice-daily dose 50mg DTG in children (20-35kgs) co-treated with RIF.
- Trial name
- ORCHID (NCT04746547)
- Testing
- Dolutegravir 50 MG, Dolutegravir 10 MG
- Where
- South Africa
- Volunteers
- 20 people
- Sponsor
- University of KwaZulu
HCV Coinfection, Liver Disease
deLIVER: Direct Acting Antiviral Effects on the Liver
Open-label, partially-randomized plasma and liver sampling study to assess hepatitis C virus (HCV) kinetics during treatment with two (Sofosbuvir/Velpatasvir) or three (Sofosbuvir/Velpatasvir/Voxilaprevir) direct acting…
- Conditions
- HCV Coinfection, Liver Disease, HIV
- Trial name
- deLIVER (NCT02938013)
- Testing
- Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX], Sofosbuvir/Velpatasvir (SOF/VEL)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Johns Hopkins University
HBV, HBV Coinfection
Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide
HDV is an RNA virus that infects only in the presence of HBV, affecting about 13% of HBsAg carriers. In Italy, prevalence ranges from 3.2% to 9.3%.
- Conditions
- HBV, HBV Coinfection, HCV, HIV Infections
- Trial name
- Bio-Delta (NCT07429864)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Human Immunodeficiency Virus, Mycobacterium Tuberculosis
Characteristics and Outcomes of TB and HIV Co-infections
People Living with HIV (PLHIV) are prone to several opportunistic infections depending on the degree of immunosuppression as well as infections prevalent in their geographic area/country.
- Trial name
- NCT06531772
- Testing
- Antitubercular Agents
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
HIV, Hepatitis C
Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections
This study will evaluate the effectiveness of pioglitazone in reducing liver fat content in patients with HIV and hepatitis C virus (HCV) infections.
- Conditions
- HIV, Hepatitis C, Liver Disease, Fatty Liver
- Trial name
- NCT00742326
- Testing
- Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection, HCV Infection
Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment
This study will evaluate efficacy of ledipasvir/sofosbuvir (LDV/SOF) and safety and tolerability of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) or emtricitabine/rilpivirine/tenofovir…
- Trial name
- Co-STARs (NCT02707601)
- Testing
- E/C/F/TAF, F/R/TAF, LDV/SOF
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- Gilead Sciences
Hepatitis C, HIV Infections
Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV
The purpose of this study is to determine whether the combination of telaprevir, peginterferon alfa-2a, and ribavirin is safe and effective in treating hepatitis C virus (HCV) infection in subjects who are infected with both HCV…
- Trial name
- NCT00983853
- Testing
- peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose)
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 62 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Tuberculosis, Pulmonary Tuberculosis
Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)
The METHOD study will examine whether adding metformin to standard antibiotic treatment for tuberculosis (TB) in people with HIV is safe and well tolerated.
- Conditions
- Tuberculosis, Pulmonary Tuberculosis, HIV Coinfection
- Trial name
- METHOD (NCT04930744)
- Testing
- Isoniazid, Rifampicin, Ethambutol
- Where
- 2 sites in South Africa
- Volunteers
- 112 people
- Sponsor
- University of Massachusetts, Worcester
Hepatitis B, HIV Infections
Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients
HBe seroconversion is an important goal for anti-HBV treatment, since it is associated with a non progressive liver infection and a better clinical outcome.
- Trial name
- HB01EMVIPEG (NCT00391638)
- Testing
- TRUVADA (EMTRICITABINE + TENOFOVIR DF), PEGASYS 180μg (Interféron pégylé alpha -2a)
- Where
- 2 sites in France
- Volunteers
- 56 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Tuberculosis, Pulmonary, HIV/AIDS
RIPE vs RIPE Plus N-acetylcysteine in Patients With HIV/TB Co-infection
Although tuberculosis is a treatable disease, it is currently the infectious disease with the highest mortality in the world. It is estimated that one-third of the world's population is infected.
- Trial name
- RIPENACTB (NCT03281226)
- Testing
- RIPE (2m) and RI (4m), RIPE+NAC (2m) and RI (4m)
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
HIV and Hepatitis B Coinfection
TAF for HIV-HBV With Renal Dysfunction
The investigators aim at describing changes in renal glomerular and tubular function with after the switch from TDF to TAF in HIV/HBV-coinfected patients with mild to moderate renal dysfunction and to assess the virological…
- Trial name
- NCT03115736
- Testing
- Tenofovir Alafenamide
- Where
- 8 sites in Switzerland
- Volunteers
- 24 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
HIV Infections, Hepatitis C
Zidovudine Levels in HIV Infected Patients Being Treated for HCV
This study will test the amount of anti-HIV drugs in the blood cells of HIV-infected patients who are also being treated for hepatitis C virus (HCV) infection.
- Trial name
- NCT00059358
- Testing
- Ribavirin plus interferon alfa-2b, Ribavirin, Peginterferon alfa-2b
- Where
- Puerto Rico
- Volunteers
- 16 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, Human Immunodeficiency Virus
HBV-HIV Coinfection Research Network
Despite effective ART that can suppress both HIV and HBV, HBV-related liver disease remains a significant co-morbidity in this population.
- Trial name
- NCT01924455
- Where
- 8 sites in United States, Canada
- Volunteers
- 139 people
- Sponsor
- Virginia Commonwealth University
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
The primary objectives of this study are to evaluate the efficacy, safety and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks in participants with chronic HCV infection who were coinfected with HIV-1.
- Trial name
- ASTRAL-5 (NCT02480712)
- Testing
- SOF/VEL
- Where
- 15 sites in United States
- Volunteers
- 107 people
- Sponsor
- Gilead Sciences